YouGotaGift launches digital rewards solution

Husain Makiya, CEO of YouGotaGift.com Ltd
Updated 24 April 2019

YouGotaGift launches digital rewards solution

YouGotaGift, a digital gift card company in the Middle East, has announced the introduction of “Rewards by YouGotaGift,” an employee rewards solution for organizations of all sizes across the region. It can be used by employers wanting to reward employees for job performance, outstanding projects, safety awards, innovation or for being chosen as employee of the month. The company already provides digital solutions for individual gifting, customer rewards and loyalty redemption.

“Every employer has a different way of rewarding their employees throughout the year, whether it be to congratulate them on a job well done, or simply to show appreciation for their efforts,” said Husain Makiya, CEO of YouGotaGift.com Ltd. 

“However, rewarding can turn into a management headache, during busy periods in particular, and good rewards ideas often fall by the wayside. Rewards by YouGotaGift makes the process of sourcing and delivering rewards a whole lot easier. It’s also fast and employees can redeem their eGift Cards at over 150 top retail brands across malls, fashion, electronics, entertainment, beauty, dining and much more.”

YouGotaGift provides eGift Cards for a variety of individual and business needs.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.